Cargando…

Current Status of Familial LCAT Deficiency in Japan

Lecithin cholesterol acyltransferase (LCAT) is a lipid-modification enzyme that catalyzes the transfer of the acyl chain from the second position of lecithin to the hydroxyl group of cholesterol (FC) on plasma lipoproteins to form cholesteryl acylester and lysolecithin. Familial LCAT deficiency is a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kuroda, Masayuki, Bujo, Hideaki, Yokote, Koutaro, Murano, Takeyoshi, Yamaguchi, Takashi, Ogura, Masatsune, Ikewaki, Katsunori, Koseki, Masahiro, Takeuchi, Yasuo, Nakatsuka, Atsuko, Hori, Mika, Matsuki, Kota, Miida, Takashi, Yokoyama, Shinji, Wada, Jun, Harada-Shiba, Mariko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Japan Atherosclerosis Society 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8265425/ https://www.ncbi.nlm.nih.gov/pubmed/33867422 http://dx.doi.org/10.5551/jat.RV17051

Ejemplares similares

Cerebrotendinous Xanthomatosis: Molecular Pathogenesis, Clinical Spectrum, Diagnosis, and Disease-Modifying Treatments
por: Koyama, Shingo, et al.
Publicado: (2021)

Current Diagnosis and Management of Tangier Disease
por: Koseki, Masahiro, et al.
Publicado: (2021)

Diagnosis and Management of Sitosterolemia 2021
por: Tada, Hayato, et al.
Publicado: (2021)

Association between Achilles Tendon Softness and Atherosclerotic Cardiovascular Disease in Patients with Familial Hypercholesterolemia
por: Michikura, Masahito, et al.
Publicado: (2022)

Guidelines for Diagnosis and Treatment of Familial Hypercholesterolemia 2017
por: Harada-Shiba, Mariko, et al.
Publicado: (2018)

Achilles Tendon Thickness Assessed by X-ray Predicting a Pathogenic Mutation in Familial Hypercholesterolemia Gene
por: Tada, Hayato, et al.
Publicado: (2022)

First-in-human autologous implantation of genetically modified adipocytes expressing LCAT for the treatment of familial LCAT deficiency
por: Aso, Masayuki, et al.
Publicado: (2022)

Two novel mutations of lecithin:cholesterol acyltransferase (LCAT) gene and the influence of APOE genotypes on clinical manifestations
por: Katayama, Akihiro, et al.
Publicado: (2011)

Guidance for Pediatric Familial Hypercholesterolemia 2017
por: Harada-Shiba, Mariko, et al.
Publicado: (2018)

Current Diagnosis and Management of Abetalipoproteinemia
por: Takahashi, Manabu, et al.
Publicado: (2021)

Familial Hypercholesterolemia and Lipoprotein Apheresis
por: Makino, Hisashi, et al.
Publicado: (2019)

Current Diagnosis and Management of Primary Chylomicronemia
por: Okazaki, Hiroaki, et al.
Publicado: (2021)

LCAT-trial-24 weeks: Protocol for a clinical study to evaluate the safety of regenerative medicine and gene therapy by the autologous transplantation of human lecithin:cholesterol acyltransferase gene-transduced human pre-adipocytes
por: Kuroda, Masayuki, et al.
Publicado: (2022)

The benign c.344G > A: p.(Arg115His) variant in the LDLR gene interpreted from a pedigree-based genetic analysis of familial hypercholesterolemia
por: Hori, Mika, et al.
Publicado: (2020)

Homozygous Familial Hypercholesterolemia
por: Nohara, Atsushi, et al.
Publicado: (2021)

Guidelines for the Diagnosis and Treatment of Adult Familial Hypercholesterolemia 2022
por: Harada-Shiba, Mariko, et al.
Publicado: (2023)

A Resuscitated Case of Acute Myocardial Infarction with both Familial Hypercholesterolemia Phenotype Caused by Possibly Oligogenic Variants of the PCSK9 and ABCG5 Genes and Type I CD36 Deficiency
por: Nishikawa, Ryo, et al.
Publicado: (2022)

Factors Associated with Carotid Atherosclerosis and Achilles Tendon Thickness in Japanese Patients with Familial Hypercholesterolemia: A Subanalysis of the Familial Hypercholesterolemia Expert Forum (FAME) Study
por: Ogura, Masatsune, et al.
Publicado: (2022)

Gradual dose Titration of Lomitapide may Prevent Therapeutic Delays in Patients with Homozygous Familial Hypercholesterolemia
por: Harada-Shiba, Mariko, et al.
Publicado: (2023)

Characterization of Polyvascular Disease in Heterozygous Familial Hypercholesterolemia: Its Association With Circulating Lipoprotein(a) Levels
por: Funabashi, Sayaka, et al.
Publicado: (2022)

Lipid Profile Rather Than the LCAT Mutation Explains Renal Disease in Familial LCAT Deficiency
por: Lamiquiz-Moneo, Itziar, et al.
Publicado: (2019)

Reference Intervals of Serum Non-Cholesterol Sterols by Gender in Healthy Japanese Individuals
por: Yoshida, Hiroshi, et al.
Publicado: (2020)

Safety and Efficacy of Lomitapide in Japanese Patients with Homozygous Familial Hypercholesterolemia (HoFH): Results from the AEGR-733-301 Long-Term Extension Study
por: Nohara, Atsushi, et al.
Publicado: (2019)

Efficacy and Safety of Lomitapide in Japanese Patients with Homozygous Familial Hypercholesterolemia
por: Harada-Shiba, Mariko, et al.
Publicado: (2017)

VLDL/LDL acts as a drug carrier and regulates the transport and metabolism of drugs in the body
por: Yamamoto, Hideaki, et al.
Publicado: (2017)

Lipoprotein X Causes Renal Disease in LCAT Deficiency
por: Ossoli, Alice, et al.
Publicado: (2016)

Toxoplasma gondii LCAT Primarily Contributes to Tachyzoite Egress
por: Schultz, Aric J., et al.
Publicado: (2018)

rHDL modeling and the anchoring mechanism of LCAT activation
por: Laurenzi, Tommaso, et al.
Publicado: (2020)

Substantially Elevated Atherosclerotic Risks in Japanese Severe Familial Hypercholesterolemia Defined by the International Atherosclerosis Society
por: Funabashi, Sayaka, et al.
Publicado: (2021)

Prospective Registry Study of Primary Dyslipidemia (PROLIPID): Rationale and Study Design
por: Tada, Hayato, et al.
Publicado: (2022)

Increase of serum uric acid levels associated with APOE ε2 haplotype: a clinico-genetic investigation and in vivo approach
por: Ogura, Masatsune, et al.
Publicado: (2021)

Circulating Mature PCSK9 Level Predicts Diminished Response to Statin Therapy
por: Kuyama, Naoto, et al.
Publicado: (2021)

Guidelines on the Clinical Evaluation of Medicinal Products for Treatment of Dyslipidemia
por: Yamashita, Shizuya, et al.
Publicado: (2020)

Familial lecithin-cholesterol acyltransferase (LCAT) deficiency; a differential of proteinuria
por: Althaf, Mohammed Mahdi, et al.
Publicado: (2015)

LCAT: an isoform-sensitive error correction for transcriptome sequencing long reads
por: Zhu, Wufei, et al.
Publicado: (2023)

Serum FABP5 concentration is a potential biomarker for residual risk of atherosclerosis in relation to cholesterol efflux from macrophages
por: Furuhashi, Masato, et al.
Publicado: (2017)

LCAT deficiency: a systematic review with the clinical and genetic description of Mexican kindred
por: Mehta, Roopa, et al.
Publicado: (2021)

Patients With LDLR and PCSK9 Gene Variants Experienced Higher Incidence of Cardiovascular Outcomes in Heterozygous Familial Hypercholesterolemia
por: Doi, Takahito, et al.
Publicado: (2021)

Guidelines for the Diagnosis and Treatment of Pediatric Familial Hypercholesterolemia 2022
por: Harada-Shiba, Mariko, et al.
Publicado: (2023)

Association between Familial Hypercholesterolemia and Serum Levels of Cholesterol Synthesis and Absorption Markers: The CACHE Study FH Analysis
por: Matsuki, Kota, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_u3ah4mtoss4c5us3e16rndh550